{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:55:48Z","timestamp":1787320548964,"version":"build-2736575974"},"reference-count":51,"publisher":"Society for Neuroscience","issue":"7","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":221,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Neurosci."],"published-print":{"date-parts":[[2018,2,14]]},"abstract":"<jats:p>\n                    Mutations in the\n                    <jats:italic>leucine-rich repeat kinase 2<\/jats:italic>\n                    (\n                    <jats:italic>LRRK2<\/jats:italic>\n                    ) gene are the most common genetic cause of Parkinson's disease (PD). The neuropathology of\n                    <jats:italic>LRRK2<\/jats:italic>\n                    mutation-related PD, including increased dopaminergic neurodegeneration and Lewy bodies, is indistinguishable from that of idiopathic PD. The subtle nonmotor phenotypes of\n                    <jats:italic>LRRK2<\/jats:italic>\n                    mutation-related PD have not been fully evaluated. In the present study, we examined anxiety\/depression-like behaviors and accompanying neurochemical changes in differently aged transgenic (Tg) mice expressing human mutant LRRK2 G2019S. Through multiple behavioral tests, including light\u2013dark test, elevated plus maze, sucrose preference test, forced swimming test, and tail-suspension test, we found that anxiety\/depression-like behavior appeared in middle-aged (43\u201352 weeks) Tg mice before the onset of PD-like motor dysfunction. These behavioral tests were performed using both male and female mice, and there were no sex-related differences in behavioral changes in the middle-aged Tg mice. Along with behavioral changes, serotonin levels also significantly declined in the hippocampus of Tg mice. Additionally, increases in the expression of the 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptor (5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    R) grew more significant with aging and were detected in the hippocampus, amygdala, and dorsal raphe nucleus.\n                    <jats:italic>In vitro<\/jats:italic>\n                    study using the serotonergic RN46A and hippocampal HT22 cells showed that 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    R upregulation was related to enhanced expression of LRRK2 G2019S and was attenuated by the LRRK2 inhibitor LRRK2-IN-1. Wild-type LRRK2 had no significant effect on 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    R transcription. The present study provides the first\n                    <jats:italic>in vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    evidence demonstrating abnormal regulation of 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    R along with the manifestation of anxiety\/depression-like, nonmotor symptom in PD related to LRRK2.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SIGNIFICANCE STATEMENT<\/jats:bold>\n                    Parkinson's disease (PD), the second most common neurodegenerative disorder, is clinically characterized by motor dysfunctions. In most cases, various nonmotor symptoms present several years before the onset of the classical motor features of PD and severely affect the quality of life of patients. Here, we demonstrate the causative role of\n                    <jats:italic>leucine-rich repeat kinase 2<\/jats:italic>\n                    (\n                    <jats:italic>LRRK2<\/jats:italic>\n                    ), a common PD-linked mutation, in the development of anxiety\/depression-like behaviors. We found that age-dependent 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptor upregulation in the hippocampus, amygdala, and dorsal raphe nucleus is accompanied by the expression of the\n                    <jats:italic>LRRK2<\/jats:italic>\n                    mutant phenotype. Our findings demonstrating a potential mechanism for nonmotor psychiatric symptoms produced by\n                    <jats:italic>LRRK2<\/jats:italic>\n                    mutation suggest that directly targeting the 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptor can improve the therapeutic efficacy of drugs for PD-associated depression.\n                  <\/jats:p>","DOI":"10.1523\/jneurosci.4051-15.2017","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T13:08:05Z","timestamp":1515157685000},"page":"1611-1621","source":"Crossref","is-referenced-by-count":52,"title":["LRRK2 G2019S Induces Anxiety\/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT\n                    <sub>1A<\/sub>\n                    Receptor Upregulation in Mice"],"prefix":"10.1523","volume":"38","author":[{"given":"Juhee","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeojin","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arum","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2837-881X","authenticated-orcid":false,"given":"Min-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-5594","authenticated-orcid":false,"given":"Kwang Hyeon","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-9525","authenticated-orcid":false,"given":"Hyun Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"key":"2023041803293044000_38.7.1611.1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2011.0376"},{"key":"2023041803293044000_38.7.1611.2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-4-21"},{"key":"2023041803293044000_38.7.1611.3","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.5b00034"},{"key":"2023041803293044000_38.7.1611.4","first-page":"252","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celada","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"2023041803293044000_38.7.1611.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(10)84017-8"},{"key":"2023041803293044000_38.7.1611.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"2023041803293044000_38.7.1611.7","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.42"},{"key":"2023041803293044000_38.7.1611.8","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26144"},{"key":"2023041803293044000_38.7.1611.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.04.021"},{"key":"2023041803293044000_38.7.1611.10","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0492-15.2016"},{"key":"2023041803293044000_38.7.1611.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2010.11.004"},{"key":"2023041803293044000_38.7.1611.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2009.11.031"},{"key":"2023041803293044000_38.7.1611.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2008.05.009"},{"key":"2023041803293044000_38.7.1611.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2005.04.016"},{"key":"2023041803293044000_38.7.1611.15","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.2000.0841"},{"key":"2023041803293044000_38.7.1611.16","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21949"},{"key":"2023041803293044000_38.7.1611.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000548"},{"key":"2023041803293044000_38.7.1611.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.02.033"},{"key":"2023041803293044000_38.7.1611.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.02.017"},{"key":"2023041803293044000_38.7.1611.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.12.038"},{"key":"2023041803293044000_38.7.1611.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.162420"},{"key":"2023041803293044000_38.7.1611.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(02)00239-1"},{"key":"2023041803293044000_38.7.1611.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2010.07161.x"},{"key":"2023041803293044000_38.7.1611.24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001920"},{"key":"2023041803293044000_38.7.1611.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034693"},{"key":"2023041803293044000_38.7.1611.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.027"},{"key":"2023041803293044000_38.7.1611.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2013.11.009"},{"key":"2023041803293044000_38.7.1611.28","first-page":"39","article-title":"Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?","volume":"91","author":"Kish","year":"2003","journal-title":"Adv Neurol"},{"key":"2023041803293044000_38.7.1611.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02550.x"},{"key":"2023041803293044000_38.7.1611.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2014.03.003"},{"key":"2023041803293044000_38.7.1611.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00484-8"},{"key":"2023041803293044000_38.7.1611.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.49"},{"key":"2023041803293044000_38.7.1611.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3430"},{"key":"2023041803293044000_38.7.1611.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00912-6"},{"key":"2023041803293044000_38.7.1611.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.09.005"},{"key":"2023041803293044000_38.7.1611.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.11.8161"},{"key":"2023041803293044000_38.7.1611.37","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.111"},{"key":"2023041803293044000_38.7.1611.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2004.03.015"},{"key":"2023041803293044000_38.7.1611.39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0031-6997(24)01417-0","article-title":"Autoregulation of serotonin neurons: role in antidepressant drug action","volume":"51","author":"Pi\u00f1eyro","year":"1999","journal-title":"Pharmacol Rev"},{"key":"2023041803293044000_38.7.1611.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.05.016"},{"key":"2023041803293044000_38.7.1611.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2014.07.037"},{"key":"2023041803293044000_38.7.1611.42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018568"},{"key":"2023041803293044000_38.7.1611.43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702723"},{"key":"2023041803293044000_38.7.1611.44","doi-asserted-by":"publisher","DOI":"10.1177\/1073858414561303"},{"key":"2023041803293044000_38.7.1611.45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fphar.2015.00162","article-title":"The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory","volume":"6","author":"Stiedl","year":"2015","journal-title":"Front Pharmacol"},{"key":"2023041803293044000_38.7.1611.46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0722238.x"},{"key":"2023041803293044000_38.7.1611.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.03919.x"},{"key":"2023041803293044000_38.7.1611.48","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-103"},{"key":"2023041803293044000_38.7.1611.49","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1523\/JNEUROSCI.14-11-06744.1994","article-title":"Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons","volume":"14","author":"White","year":"1994","journal-title":"J Neurosci"},{"key":"2023041803293044000_38.7.1611.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.02.042"},{"key":"2023041803293044000_38.7.1611.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.12.025"}],"container-title":["The Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.4051-15.2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T07:19:17Z","timestamp":1751181557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jneurosci.org\/lookup\/doi\/10.1523\/JNEUROSCI.4051-15.2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,2,14]]},"published-print":{"date-parts":[[2018,2,14]]}},"alternative-id":["10.1523\/JNEUROSCI.4051-15.2017"],"URL":"https:\/\/doi.org\/10.1523\/jneurosci.4051-15.2017","relation":{},"ISSN":["0270-6474","1529-2401"],"issn-type":[{"value":"0270-6474","type":"print"},{"value":"1529-2401","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,5]]}}}